Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245634 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT01245634 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 384 participants.
The verdict
NCT01245634, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to receive either RO4905417 20 mg/kg by intravenous infusion or placebo every 4 weeks for 32 weeks.
Interventions
- DRUG Placebo
- DRUG RO4905417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245634
The ClinicalTrials.gov registry entry for NCT01245634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01245634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01245634 about?
NCT01245634 is a clinical study titled "A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery". This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to receive either RO4905417 20 mg/k...
What is the current status of trial NCT01245634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2010-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01245634?
The interventions under investigation include: Placebo (DRUG), RO4905417 (DRUG).
Who is sponsoring clinical trial NCT01245634?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.